# Bristol-Myers Squibb Company (BMY) — Q3-2012 Earnings Results

**Report date:** 2012-10-24 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/BMY/earnings/Q3-2012

## Post-Earnings Brief

### Headline

Bristol Myers Squibb Misses on EPS, Stock Down 0.57%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.41 | N/A | -0.97% |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management remains focused on long-term growth despite the slight EPS miss. They emphasized the strength of their product portfolio.

**Key quotes:**

> Management expressed confidence in ongoing product pipeline.

> They highlighted the importance of upcoming clinical trial results.

### Guidance Changes

No guidance updates were provided during the earnings call.

### What It Means

Bristol Myers Squibb's earnings report showed a slight miss on EPS, which contributed to a small decline in the stock price. Investors may be cautious due to the lack of revenue data and forward guidance. The management's focus on the product pipeline suggests they are looking to future growth despite current challenges.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/BMY/earnings/Q3-2012_